Press release
Gemini Therapeutics Announces ASCO 2026 Analyses Supporting Aldoxorubicin’s Tumor-Targeted Delivery and Cardiac-Safety Profile
May 27, 2026
Integrated analyses show higher tumor exposure than doxorubicin and better preservation of cardiac function in randomized soft tissue sarcoma studies despite approximately 3.5-fold higher cumulative doxorubicin-equivalent exposure.
Read the release